Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Genistein nanoparticle - Humanetics Corporation

Drug Profile

Genistein nanoparticle - Humanetics Corporation

Alternative Names: BIO-300

Latest Information Update: 26 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Armed Forces Radiobiology Research Institute; National Institutes of Health (USA); United States Department of Defense
  • Developer Armed Forces Radiobiology Research Institute; Henry Ford Health System; Humanetics Corporation; Medical College of Wisconsin; Milwaukee VA Medical Center; National Institutes of Health (USA); University of Maryland, Baltimore
  • Class Antifibrotics; Antineoplastics; Chemosensitisers; Isoflavones; Osteoporosis therapies; Phytotherapies; Radioprotectives; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis inhibitors; Apoptosis stimulants; Cell cycle modulators; DNA repair enzyme modulators; Haematopoietic cell growth factor stimulants; Inflammation mediator modulators; Protein tyrosine kinase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pulmonary fibrosis
  • Phase I/II Radiation injuries
  • Phase I Acute radiation syndrome

Most Recent Events

  • 19 Sep 2023 Efficacy, pharmacokinetics and adverse events data from a phase-I/II trial in Radiation injuries released by Humanetics Corporation
  • 24 May 2023 Pharmacodynamics data from a non-clinical trial in Radiation injuries released by Humanetics Corporation
  • 07 Feb 2023 Development for phase-I in Acute-radiation-syndrome(Prevention) is ongoing in USA (PO, Capsule)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top